...
首页> 外文期刊>Urologic oncology >Strategies for targeted tumor assessment and elimination: the physician-scientist and the blossoming of molecular medicine in urologic oncology.
【24h】

Strategies for targeted tumor assessment and elimination: the physician-scientist and the blossoming of molecular medicine in urologic oncology.

机译:有针对性的肿瘤评估和消除策略:医师,泌尿外科肿瘤学领域的分子医学蓬勃发展。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

To realize its full potential in treating urologic malignancies, molecular medicine in the post-genomic era requires the science of molecular biology to become a great force of change directed to the critical health questions confronting the clinician. The clinician-scientist is the linchpin to convert an exploratory, reactive stance to a predictive and efficacious paradigm in treating urologic malignancies. The explosion of basic and translational discoveries will demand a "systems biology" approach at the fingertips of the future clinician, and realize the dream of proactive and highly adaptable "engineered" response to the very complex "survival" biology of urologic tumors. To arm our clinicians of tomorrow, the physician-scientists of today need resources, time, and a nurturing environment to ask great questions, and, thus, to solve the problem of cancer.
机译:为了充分发挥其在泌尿外科恶性肿瘤治疗中的潜力,后基因组时代的分子医学要求分子生物学成为针对临床医生面临的重要健康问题的巨大变革力量。临床科学家是治疗泌尿系统恶性肿瘤时将探索性,反应性态度转变为预测性和有效范例的关键。基础和转化发现的爆炸式增长将需要未来临床医生触手可及的“系统生物学”方法,并实现对泌尿系统肿瘤非常复杂的“生存”生物学主动且高度适应的“工程化”反应的梦想。为了武装我们明天的临床医生,今天的医师科学家需要资源,时间和培育环境来提出重要问题,从而解决癌症问题。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号